Navigate this Section

Sue Desmond-Hellmann, MD, MPH, is a physician-scientist who led the development of the first gene-targeted drug for treating breast cancer.

  • Medical, scientific, and philanthropic career spanning 40 years: from academic medicine and clinical practice studying cancer and HIV/AIDS, to running research and product development at some of America’s top biotechnology companies, to leading higher education at one of California’s marquis graduate institutions, to running the world’s largest private foundation.
  • Former Chancellor of the University of California, San Francisco (2009-2014), and the first woman to hold the position.
  • At the leading biotech firm Genentech (1995-2009), led development of Herceptin® and served as Chief Medical Officer.
  • Member of U.S. National Academy of Medicine.
  • Co-chaired influential National Academies report that defined and charted the course of precision medicine.

Stay Connected

We'll be in touch with the latest information on how President Biden and his administration are working for the American people, as well as ways you can get involved and help our country build back better.

Scroll to Top
Top